VolitionRX Enhances Nu.Q® Vet Test Accessibility Through New Partnerships for Early Cancer Detection

VolitionRX Expands Availability of Nu.Q® Vet Cancer Test with New Partnerships

VolitionRx Limited, a leading name in epigenetics, announces a significant advancement in the accessibility of its Nu.Q® Vet Cancer test through the appointment of two centralized laboratory providers. As of February 2026, the Midwest Veterinary Laboratory, an independent reference lab, will distribute the test across all 50 states in the U.S., enhancing the reach of this critical diagnostic tool. Concurrently, Bioguard, a prominent global player in animal health diagnostics, will offer the test from its Animal Health Diagnostic Center, which stands as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. These strategic partnerships not only broaden the geographic footprint of the Nu.Q® Vet test but also signify a pivotal move towards improving early cancer detection in dogs, catering to a significant and growing market.

Dr. Tom Butera, CEO of Volition Veterinary Diagnostics Development LLC, emphasizes the company’s commitment to making advanced diagnostic technologies accessible to veterinary professionals. By expanding the availability of the Nu.Q® Vet test, VolitionRx aims to empower veterinarians and pet owners with the tools necessary for timely intervention in canine health issues. The early detection capabilities of the Nu.Q® Vet test are designed to provide crucial insights that can lead to improved health outcomes, fostering a proactive approach to veterinary care. This development aligns with VolitionRx's broader mission of enhancing health outcomes for both humans and animals through innovative and cost-effective blood tests.

The market potential for the Nu.Q® Vet test is substantial, with the total addressable market estimated at around $100 million across the U.S., Europe, and Japan. The introduction of the test in China could further expand this figure to nearly $150 million. VolitionRx’s focus on research and development, particularly in Belgium, alongside its strategic initiatives, positions the company favorably within the veterinary diagnostics arena, aiming to revolutionize early disease detection through epigenetics.

In addition to its recent partnerships, VolitionRx continues to concentrate its research and development efforts on a range of diseases linked to NETosis, demonstrating its commitment to advancing the science of epigenetics. With offices located in the U.S. and London, the company remains poised for growth, driven by a vision to save lives through timely and effective disease detection methods. The strategic partnerships and innovative technologies underscore VolitionRx’s dedication to enhancing the quality of care for animals worldwide, ultimately benefiting veterinarians and pet owners alike.